title: Reply: To PMID 23881226.
authors: *Department of Ophthalmology, University Hospitals Leuven, Leuven, Belgium †Department of Ophthalmology, New England Eye Center and Tufts Medical Center, Tufts University, Boston, Massachusetts.
authors: Peter
authors: P
authors: Stalmans
authors: Jay S
authors: JS
authors: Duker
mesh_terms: D005128:Eye Diseases / Q000175:diagnosis*; D005341:Fibrinolysin / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D010446:Peptide Fragments / Q000627:therapeutic use*; D012164:Retinal Diseases / Q000175:diagnosis*; D012167:Retinal Perforations / Q000188:drug therapy*; D041623:Tomography, Optical Coherence; D014822:Vitreous Body / Q000473:pathology*; D020255:Vitreous Detachment / Q000188:drug therapy*
chemical_list: D005343:Fibrinolytic Agents; D010446:Peptide Fragments; D005341:Fibrinolysin